CHEK2 is identified as a susceptibility gene for pheochromocytomas and paragangliomas (Gao et al., 2021), and CHEK2 mutations are associated with the survival of patients with stage T1 bladder cancer (Złowocka-Perłowska et al., 2021). Here, CHEK2 is linked to hereditary pheochromocytoma-paraganglioma.